ethyl 4'-cyanooxanilate | 24439-47-2

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: ethyl 4'-cyanooxanilate
• 英文别名: (4-cyano-phenyl)-oxalamic acid ethyl ester；(4-Cyan-phenyl)-oxalamidsaeure-aethylester；Oxalsaeure-aethylester-(4-cyan-anilid)；4-Cyan-oxanilsaeureaethylester；[(4-cyanophenyl)amino]oxo-acetic acid, ethyl ester；4-Cyan-oxanilsaeureethylester；Ethyl [(4-cyanophenyl)carbamoyl]formate；ethyl 2-(4-cyanoanilino)-2-oxoacetate
• CAS: 24439-47-2
• 化学式: C₁₁H₁₀N₂O₃
• mdl: MFCD02575689
• 分子量: 218.212
• InChiKey: UIAIEGFHSDPSAA-UHFFFAOYSA-N

物化性质

• 熔点：
  188.5-189 °C(Solv: ethanol (64-17-5))
• 密度：
  1.25±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  16
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  79.2
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  ethyl 4'-cyanooxanilate 在 氨 作用下， 生成 (4-cyano-phenyl)-oxalamide
  参考文献：
  名称：

  Bogert; Wise, Journal of the American Chemical Society, 1912, vol. 34, p. 701

  摘要：

  DOI：
• 作为产物：
  描述：

  草酰氯单乙酯 、 对氨基苯腈 在 三乙胺 作用下， 以 四氢呋喃 为溶剂， 以39%的产率得到ethyl 4'-cyanooxanilate
  参考文献：
  名称：

  Rapid Microwave-Assisted Syntheses of Derivatives of HIV-1 Entry Inhibitors

  摘要：

  通过计算机控制的微波辐射，在甲苯中实现了酯与4-氨基-2,2,6,6-四甲基哌啶的直接酰胺化。微波方法使新酰胺的制备时间缩短至三小时，而传统热法则需要三天。

  DOI：

  10.1055/s-2006-926339

文献信息

• Discovery of Cytochrome P450 4F11 Activated Inhibitors of Stearoyl Coenzyme A Desaturase
  作者：Sarah E. Winterton、Emanuela Capota、Xiaoyu Wang、Hong Chen、Prema L. Mallipeddi、Noelle S. Williams、Bruce A. Posner、Deepak Nijhawan、Joseph M. Ready

  DOI：10.1021/acs.jmedchem.8b00052

  日期：2018.6.28

  Stearoyl-CoA desaturase (SCD) catalyzes the first step in the conversion of saturated fatty acids to unsaturated fatty acids. Unsaturated fatty acids are required for membrane integrity and for cell proliferation. For these reasons, inhibitors of SCD represent potential treatments for cancer. However, systemically active SCD inhibitors result in skin toxicity, which presents an obstacle to their development

  硬脂酰辅酶A去饱和酶（SCD）催化饱和脂肪酸向不饱和脂肪酸转化的第一步。膜完整性和细胞增殖需要不饱和脂肪酸。由于这些原因，SCD抑制剂代表了潜在的癌症治疗方法。但是，具有内在活性的SCD抑制剂会导致皮肤毒性，这对它们的发展构成了障碍。我们最近描述了一系列草酸二酰胺，它们通过CYP4F11介导的代谢转化为癌症子集内的活性SCD抑制剂。在本文中，我们描述了草酸二酰胺和相关N-酰基脲的优化，以及与代谢活化和SCD抑制有关的结构-活性关系的分析。
• 2,3-quinoxalinediones for use as neuroleptics
  申请人：Novo Nordisk A/S

  公开号：US05061706A1

  公开（公告）日：1991-10-29

  Heterocyclic dihydroxyquinoxaline compounds having the formula ##STR1## wherein R.sup.1 is hydroxy, alkoxy, aryloxy, aralkyloxy, cycloalkylalkoxy, cycloalkoxy, or acyloxy; and R.sup.5, R.sup.6, R.sup.7 and R.sup.8 independently are hydrogen, NO.sub.2, halogen CN, SO.sub.2 NR'R', SO.sub.2 R', CF.sub.3, or OR', wherein R' is hydrogen or C.sub.1-4 -alkyl; The invention also relates to a method of preparing the compounds, pharmaceutical compositions thereof, and their use. The compounds are useful in the treatment of indications caused by hyperactivity of the excitatory neurotransmitters, particularly the quisqualate receptors, and especially as neuroleptics.

  具有以下式子的杂环二羟基喹喔啉化合物：##STR1## 其中R.sup.1是羟基，烷氧基，芳氧基，芳基烷氧基，环烷基烷氧基，环烷氧基或酰氧基；R.sup.5，R.sup.6，R.sup.7和R.sup.8分别是氢，NO.sub.2，卤素CN，SO.sub.2NR'R'，SO.sub.2R'，CF.sub.3或OR'，其中R'是氢或C.sub.1-4-烷基。本发明还涉及制备该化合物的方法，其药物组成物及其用途。该化合物在治疗由兴奋性神经递质过度活跃引起的症状中是有用的，特别是在治疗谷氨酸受体方面，尤其是作为神经精神药物。
• Quinoxaline compounds and their preparation and use
  申请人：NOVO NORDISK A/S

  公开号：EP0377112A1

  公开（公告）日：1990-07-11

  Heterocyclic dihydroxyquinoxaline compounds having the formula wherein R¹ is hydroxy, alkoxy, aryloxy, aralkyloxy, cycloalkylalkoxy, cycloalkoxy, or acyloxy; and R⁵, R⁶, R⁷ and R⁸ independently are hydrogen, NO₂, halogen, CN, SO₂NR′R′, SO₂R′, CF₃, or OR′, wherein R′ is hydrogen or C1-4-alkyl. The invention also relates to a method of preparing the compounds, pharmaceutical compositions thereof, and their use. The compounds are useful in the treatment of indications caused by hyperactivity of the excitatory neurotransmitters, particularly the quisqualate receptors, and especially as neuroleptics.

  具有以下式子的杂环二羟基喹喔啉化合物 其中 R¹ 是羟基、烷氧基、芳氧基、烷氧基、环烷基烷氧基、环烷氧基或酰氧基；以及 R⁵、R⁶、R⁷ 和 R⁸ 独立地是氢、NO₂、卤素、CN、SO₂RN′R′、SO₂R′、CF₃ 或 OR′，其中 R′是氢或 C1-4 烷基。 本发明还涉及化合物的制备方法、其药物组合物及其用途。 本发明的化合物可用于治疗兴奋性神经递质，特别是喹乙醇受体活性亢进引起的病症，尤其可用作神经抑制剂。
• Chemical Hybridizing Agents for Chickpea (<i>Cicer arietinum</i> L.):  Leads from QSAR Analysis of Ethyl Oxanilates and Pyridones
  作者：Kajal Chakraborty、C. Devakumar

  DOI：10.1021/jf052435h

  日期：2006.3.1

  In the self-pollinated crops such as chickpea, induction of male sterility by deployment of chemical hybridizing agents (CHAs) facilitating "two-line" approach holds immense potential in heterosis breeding. A total of 40 test CHAs comprising 20 ethyl oxanilates and 20 pyridones were screened as potential CHAs on chickpea (variety BG 1088) at 500, 800, and 1000 ppm. Three test compounds mostly having either F (4)/Br (5)/CF3 (19) at the para position of the aryl ring from a pool of 20 ethyl oxanilates were identified as the most potent CHAs causing >= 99% induction of pollen sterility and > 90% total flower sterility at 1000-ppm test concentration. Among pyridone derivatives, N-(4-chlorophenyl)-5-carbethoxy-4,6-dimethyl, 1, 2-dihydropyrid-2-one (26) was found to be the most active. Quantitative structure activity relationship (QSAR) analysis has revealed a direct involvement of Swain-Lupton field constant, F, with the target bioactivity which implied that field rather than resonance effect (R) had a positive effect on the activity. The real guiding principle for selectivity was found out to be the hydrophobic parameter pi value. The QSAR models indicated that increased steric bulk at the 4-position on the phenyl ring is associated with enhanced activity. The CHAs appeared to act by mimicking UDP-glucose, the key substrate in the synthesis of callose, or lead to an imbalance in acid-base equilibrium in pollen mother cells resulting in dissolution of callose wall by premature callase secretion.
• FR1516276
  申请人：——

  公开号：——

  公开（公告）日：——